In this review, the authors describe the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the new quinolones (levofloxacin, gatifloxacin, moxifloxacin, gemifloxacin, and garenoxacin) and discuss their implications on adequate therapy of patients with respiratory infections. The newer quinolones display excellent bioavailability and have longer serum half-lives than ciprofloxacin. In addition, they have the ability to concentrate in respiratory tract tissues and fluids at levels that exceed serum-drug concentrations. Also, the newer quinolones exhibit broad-spectrum activity against both susceptible and resistant organisms. Those favorable PK/PD properties make the new quinolones an attractive therapeutic alternative to traditional agents for common respiratory infections. Understanding the PK/PD of quinolone antibiotics can facilitate selection of optimal regimens to hasten response, prevent treatment failures, and minimize the development of resistance.
Blondeau JM. Expanded activity and utility of the new fluoroquinolones. A review. Clin Ther. 1999;21:3-3.
2.
Schentag JJ, Scully BE. Quinolones. In: Yu VL, Merigan TC Jr, Barriere S, eds. Antimicrobial Therapy and Vaccines. Baltimore: Williams & Wilkins; 1999:875-875.
3.
Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs. 1996;51(6):1019-1074.
4.
Naber KGTheuretzbacher U, Moneva-Koucheva G, Stass H.Uri-nary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin. Eur J Clin Microbiol Infect Dis. 1999;18(11):783-789.
5.
Schuler P, Zemper K, Borner K, Koeppe P, Schaberg T, Lode H.Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. Eur Respir J. 1997;10(5):1130-1136.
6.
Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties. 35th ed.Ottawa: Canadian Pharmacists Association; 2000:322-325, 838-841.
Bron NJ, Dorr MB, Mant TG, Webb CL, Vassos AB. The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects. J Antimicrob Chemother. 1996;38(6):1023-1029.
9.
Wise R, Jones S, Das I, Andrews JM. Pharmacokinetics and inflammatory fluid penetration of clinafloxacin. Antimicrob Agents Chemother. 1998;42(2):428-430.
10.
Randinitis EJ, Brodfuehrer J, Vassos AB. Pharmacokinetics of clinafloxacin following oral and intravenous single and multiple dosing in volunteers [abstr]. In: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 1998.
11.
Randinitis EJ, Koup JR, Rausch G, et al. Single-dose clinafloxacin pharmacokinetics in subjects with various degrees of renal function [abstr]. In: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 1998.
12.
Wise R, Ashby JP, Andrews JM. In vitro activity of PD 127,391, an enhanced-spectrum quinolone. Antimicrob Agents Chemother. 1998;32(8):1251-1256.
13.
Nakashima M, Uematsu T, Kosuge K, et al. Single and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother. 1995;39(12):2635-2640.
14.
Bristol-Myers Squibb. Package insert: Gatifloxacin. New York: Bristol-Myers Squibb; 2001.
15.
Wise R, Andrews JM, Da Ros L, Child J, Mortiboy D.A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose. J Antimicrob Chemother. 1999;44(5):701-704.
16.
LaCreta FP, Kaul S, Kollia GD, Duncan G, Randall DM, Grasela DM. Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults [In Process Citation]. Pharmacotherapy. 2000;20(6 Pt 2):59S-66S.
17.
LaCreta FP, Kollia GD, Duncan G, Behr D, Grasela DM. Age and gender effects on the pharmacokinetics of gatifloxacin [In Process Citation]. Pharmacotherapy. 2000;20(6 Pt 2):67S-75S.
18.
Grasela DM, Christofalo B, Kollia GD, et al. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment [In Process Citation]. Pharmacotherapy. 2000;20(6 Pt 2):87S-94S.
19.
Abramowicz ME. Gatifloxacin and moxifloxacin: two new fluoroquinolones. Medical Lett. 2000;42(1072):15-17.
20.
Lober S, Ziege S, Rau M, et al. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob Agents Chemother. 1999;43(5):1067-1071.
21.
Allen A, Bygate E, Clark D, Lewis A, Pay V.The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers. Int J Antimicrob Agents. 2000;16(1):45-50.
22.
Allen A, Bygate E, Faessel H, Isaac L, Lewis A.The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers. Int J Antimicrob Agents. 2000;15(4):283-289.
23.
Saliba F, Issac L, Barker PJ, et al. The pharmacokinetics and tolerability of a single oral dose of gemifloxacin in patients with mild or moderate hepatic impairment [poster]. In: 3rd European Congress of Chemotherapy, Madrid, Spain, 2000.
24.
Allen A, Bygate E, Oliver S.Distribution of gemifloxacin into saliva, sweat, tears and nasal secretion in healthy volunteers [poster]. In: 3rd European Congress of Chemotherapy, Madrid, Spain, 2000.
25.
Allen A, Pletz MW, Petzold P, Burhardt O, Lode H.Pharmacokinetics of gemifloxacin administered to patients with severe renal impairment and patients on dialysis [poster]. In: 3rd European Congress of Chemotherapy, Madrid, Spain, 2000.
26.
Efthymiopoulos C, Bramer SL, Maroli A, Gambertoglio JG. Effect of renal impairment on the pharmacokinetics of grepafloxacin. Clin Pharmacokinet. 1997;33(Suppl 1):32-38.
27.
Child J, Andrews JM, Wise R.Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. Antimicrob Agents Chemother. 1995;39(2):513-515.
28.
Efthymiopoulos C, Bramer SL, Maroli A.Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. Clin Pharmacokinet. 1997;33(Suppl 1):1-8.
29.
Kozawa O, Uematsu T, Matsuno H, Niwa M, Nagashima S, Kanamaru M.Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects. Antimicrob Agents Chemother. 1996;40(12):2824-2828.
30.
Efthymiopoulos C, Bramer SL, Maroli A, et al. Grepafloxacin pharmacokinetics in individuals with hepatic dysfunction. Clin Pharmacokinet. 1997;33(Suppl 1):25-31.
31.
Efthymiopoulos C, Bramer SL, Maroli A.Effect of food and gastric pH on the bioavailability of grepafloxacin. Clin Pharmacokinet. 1997;33(Suppl 1):18-24.
32.
Chien SC, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother. 1997;41(10):2256-2260.
33.
Chien SC, Chow AT, Natarajan J, et al. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother. 1997;41(7):1562-1565.
34.
Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997;32(2):101-119.
35.
Gotfried MH, Danzinger LH, Rodvold K.Steady state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest. 2001;119:1114-1122.
36.
Andrews JM, Honeybourne D, Jevons G, Brenwald NP, Cunningham B, Wise R.Concentration of levofloxacin (HR 355) in the respiratory tract following a single dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 1997;40:573-577.
37.
Chien SC, Wong FA, Fowler CL, et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother. 1998;42(4):885-888.
38.
Stass H, Kubitza D.Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother. 1999;43(Suppl B):83-90.
39.
Stass H, Dalhoff A, Kubitza D, Schuhly U.Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother. 1998;42(8):2060-2065.
40.
Sullivan JT, Woodruff M, Lettieri J, et al. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother. 1999;43(11):2793-2797.
41.
Wise R, Andrews JM, Marshall G, Hartman G.Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother. 1999;43(6):1508-1510.
42.
Stass H, Halabi A, Delesen H.No dose adjustment needed for patient’s with renal impairment receiving oral BAY 12-8039 [abstr]. In: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 1998.
43.
Stass H, Kubitza D, Schuhly U.No dose adjustment is needed for moxifloxacin in subjects suffering from hepatic impairment [abstr]. In: 9th European Congress of Clinical Microbiology and Infectious Disease, Berlin, 1999.
44.
Nakashima M, Uematsu T, Kosuge K, Umemura K, Hakusui H, Tanaka M.Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers [published erratum appears in Antimicrob Agents Chemother. 1995;39(4):1015]. Antimicrob Agents Chemother. 1995;39(1):170-174.
45.
Johnson JH, Cooper MA, Andrews JM, Wise R.Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother. 1992;36(11):2444-2446.
46.
Montay G, Bruno R, Vergniol JC, et al. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg. J Clin Pharmacol. 1994;34(11): 1071-1076.
Montay G.Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review. J Antimicrob Chemother. 1996;37(Suppl A):27-39.
49.
Kamberi M, Kotegawa T, Tsutsumi K, Nakamura K, Nakano S.Sparfloxacin pharmacokinetics in healthy volunteers: the influence of acidification and alkalinization. Eur J Clin Pharmacol. 1998;54(8):633-637.
50.
Johnson R, Geary W, Jenssen B.The absolute oral bioavailability of sparfloxacin in healthy male subjects [abstr]. In: 36th Interscience Conference on Antimicrobial Agents and Chemo-therapy, New Orleans, LA, 1996.
51.
Zix JA, Geerdes-Fenge HF, Rau M, et al. Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. Antimicrob Agents Chemother. 1997;41(8):1668-1672.
52.
Fillastre JP, Montay G, Bruno R, et al. Pharmacokinetics of sparfloxacin in patients with renal impairment. Antimicrob Agents Chemother. 1994;38(4):733-737.
53.
Ritz M, Lode H, Fassbender M, Borner K, Koeppe P, Nord CE. Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. Antimicrob Agents Chemother. 1994;38(3):455-459.
54.
Mugnier P, Taubert AM, Wyld PJ, et al. Pharmacokinetics of sparfloxacin in patients with hepatic failure [abstr]. In: 34th Interscience Conference on Antimicrobial Agents and Chemo-therapy, Washington, DC, 1994.
55.
Melnik G, Schwesinger WH, Teng R, Dogolo LC, Vincent J.Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers. Eur J Clin Microbiol Infect Dis. 1998;17(6):424-426.
56.
Vincent J, Dogolo L, Baris BA, Willavize SA, Teng R.Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans. Eur J Clin Microbiol Infect Dis. 1998;17(6):427-430.
57.
Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J.Oral bioavailability of trovafloxacin with and without food in healthy volunteers. J Antimicrob Chemother. 1997;39(Suppl B):87-92.
58.
Teng R, Liston TE, Harris SC. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother. 1996;37(5):955-963.
59.
Teng R, Harris SC, Nix DE, Schentag JJ, Foulds G, Liston TE. Pharmacokinetics and safety of trovafloxacin (CP-99, 219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother. 1995;36(2):385-394.
60.
Vincent J, Teng R, Dalvie DK, Friedman HL. Pharmacokinetics and metabolism of single oral doses of trovafloxacin. Am J Surg. 1998;176(6A Suppl):8S-13S.
61.
Wise R, Mortiboy D, Child J, Andrews JM. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99, 219). Antimicrob Agents Chemother. 1996;40(1):47-49.
62.
Gajjar DA, Sukoneck SC, Bello A, Ge Z, Christopher L, Grasela DM. Effect of a high-fat meal on the pharmacokinetics of the desF(6)-quinolone BMS-284756. Pharmacotherapy. 2002;22:160-165.
63.
Russo R, Bello A, Christopher L, Gajjar DA. Lack of effect of a high-fat meal on the bioavailability of garenoxacin oral suspension in healthy subjects. ASHP Midyear Clin Meeting. 2002;37:P328E-P328E.
64.
Bello A, Farmer J, O’Mara E, Christopher L, Gajjar DA. Pharmacokinetics and disposition of garenoxacin in healthy adult male subjects. ASHP Midyear Clin Meeting. 2002;37:P321E-P321E.
65.
Bello A, Stewart C, O’Mara E, Christopher L, Gajjar DA. Absolute oral bioavailability of garenoxacin tablets and the bioequivalence of the intravenous formulation with respect to oral tablets. ASHP Midyear Clin Meeting. 2002;37:P331E-P331E.
66.
Wise R, Gee T, Marshall G, Andrews JM. Single-dose pharmacokinetics and penetration of BMS 284756 into an inflammatory exudate. Antimicrob Agents Chemother. 2002;46:242-244.
67.
Rodriguez-Cerrato V, Ghaffar F, Saavedra J, et al. BMS-284756 in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother. 2001;45:3098-3103.
68.
Vincent J, Venitz J, Teng R, et al. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. J Antimicrob Chemother. 1997;39(Suppl B):75-80.
69.
LaCreta F, Kollia GD, Duncan G, Behe D, Grasela DM. Effect of a high-fat meal on the bioavailability of gatifloxacin in healthy volunteers [abstr]. In: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 1998.
70.
Wilson APR, Gruneberg RN. Ciprofloxacin: 10 Years of Clinical Experience. Somerset, UK: Maxim Medical; 1997:67-67.
71.
Wise R, Honeybourne D.A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. J Antimicrob Chemother. 1996;37(Suppl A):57-63.
72.
Honeybourne D, Andrews JM, Cunningham B, Jevons G, Wise R.The concentrations of clinafloxacin in alveolar macrophages, epithelial lining fluid, bronchial mucosa and serum after administration of single 200 mg oral doses to patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 1999;43(1):153-155.
73.
Tanimura H, Uchiyama K, Kashiwagi H.Gallbladder tissue concentrations, biliary excretion and pharmacokinetics of OPC-17116. Drugs. 1995;49(Suppl 2):341-343.
74.
Takahashi Y, Itoh Y, Dot T, Kuryaama Y.Penetration of OPC-17116, a new quinolone compound, into male genital tracts and its in vitro antibacterial activity [abstr]. In: 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991.
75.
Suzuki K, Horiba M.Penetration of OPC-17116, a new quinolone derivative, into human prostatic fluid [abstr]. In: 31st Interscience Conference on Antimicrobial Agents and Chemo-therapy, Chicago, IL, 1991.
76.
Cook PJ, Andrews JM, Wise R, Honeybourne D, Moudgil H.Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother. 1995;35(2):317-326.
77.
Ohnishi H, Tanimura H, Okamura T, et al. Excretion of levofloxacin into bile and gallbladder tissue [abstr]. Drugs. 1993;45(Suppl 3):260-261.
78.
Child J, Mortiboy D, Andrews JM, Chow AT, Wise R.Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antimicrob Agents Chemother. 1995;39(12):2749-2751.
79.
Muller M, Stass H, Brunner M, Moller JG, Lackner E, Eichler HG. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother. 1999;43(10):2345-2349.
80.
Soman A, Honeybourne D, Andrews J, Jevons G, Wise R.Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 1999;44(6):835-838.
81.
Wise R.A review of the clinical pharmacology of moxifloxacin, a new 8-methoxy quinolone and its potential relationship to therapeutic efficacy. Clin Drug Invest. 1999;17(5):365-387.
82.
Andrews J, Wise R, Jennifer M, Marshall G, Hartmann G.Penetration of Bay 12-8039 into bronchial mucosa, epithelial lining [abstr]. In: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 1998.
83.
Cutler NR, Vincent J, Jhee SS, et al. Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin. Antimicrob Agents Chemother. 1997;41(6):1298-1300.
84.
Childs S, Gleason D, Immergut M, et al. Penetration of trovafloxacin into prostatic tissue following multiple dosing in man [abstr]. In: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, 1997.
85.
Andrews JM, Honeybourne D, Brenwald NP, et al. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 1997;39(6):797-802.
86.
Peleman RA, Van De Velde V, Germonpre PR, Fleurinck C, Rosseel MT, Pauwels RA. Trovafloxacin concentrations in airway fluids of patients with severe community-acquired pneumonia. Antimicrob Agents Chemother. 2000;44(1):178-180.
87.
Naber C, Hammer M, Kinzig-Schippers M, et al. Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers. Antimicrob Agents Chemother. 2001;45(12):3524-3530.
88.
Allen A, Sorgel F, Pay V, et al. Distribution of gemifloxacin into saliva sweat tears and nasal secretions in healthy volunteers [abstr]. In: 11th European Congress Clinical Microbiology and Infectious Diseases, Istanbul, Turkey, 2001.
89.
Wise R, Gee T, Andrews JM, Ashby JP, Marshall G.The pharmacokinetics and inflammatory fluid penetration of gemifloxacin [abstr]. In: 11th European Congress Clinical Micro-biology and Infectious Diseases, Istanbul, Turkey, 2001.
90.
Gatifloxacin and moxifloxacin: two new fluoroquinolones. Med Lett Drugs Ther. 2000;42(1072):15-17.
91.
Bradley JS, Kearns GL, Reed MD, Capparelli EV, Vincent J.Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin. Antimicrob Agents Chemother. 2000;44(5):1195-1199.
92.
Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics [In Process Citation]. Pharmacotherapy. 2000;20(3):245-256.
93.
Lacy MK, Nicolau DP, Nightingale CH, et al. Oral bioavailability and pharmacokinetics of trovafloxacin in patients with AIDS. Antimicrob Agents Chemother. 1999;43(12):3005-3007.
94.
Goodwin SD, Gallis HA, Chow AT, Wong FA, Flor SC, Bartlett JA. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1994;38(4):799-804.
95.
Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1-10; quiz 11-12.
96.
Drusano GL. Antimicrobial pharmacodynamic critical interaction of “bug and drug.”Nat Rev Microbiol. 2004;2(4):289-300.
97.
Ambrose PG, Owens RC. New antibiotics in pulmonary and critical care medicine: focus on advanced generation quinolones and cephalosporins. Sem Resp Crit Care Med. 2000;21(1):19-32.
98.
Dalhoff A.Pharmacodynamics of fluoroquinolones. J Antimicrob Chemother. 1999;43(Suppl B):51-59.
Pickerill KE, Paladino JA, Schentag JJ. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy. 2000;20(4):417-428.
101.
Stein GE. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis. 1996;23(Suppl 1):S19-S24.
102.
Schentag JJ, Nix DX, Forrest A.Pharmacodynamics of the fluoroquinolones. In: Hooper DC, Wolfson JS, eds. Quinolone Antimicrobial Agents. 2nd ed.Washington, DC: American Society for Microbiology; 1993:259-271.
Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet. 1995;28:143-160.
105.
Bowker KE, Wootton M, Rogers CA, Lewis R, Holt HA, MacGowan A.Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin. J Antimicrob Chemother. 1999;44(5):661-667.
106.
Madaras-Kelly KJ, Ostergaard BE, Hovde LB, Rotschafer JC. Twenty-four hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 1996;40:627-632.
107.
Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilimicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance. Antimicrob Agents Chemother. 1987;31:1054-1060.
108.
MacGowan AP, Bowker KE, Wootton M, Holt HA. Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniaein an in vitro pharmacodynamic model of infection. Antimicrob Agents Chemother. 1999;43(7):1560-1564.
109.
Hoang AD, Raddatz JK, Hovde LB, Rotschafer JC. An in-vitro pharmacodynamic evaluation of levofloxacin against four strains of penicillin resistant S. pneumoniae [abstr]. In: 78th American Society for Microbiology, Miami, FL, 1997.
110.
Hershberger E, Rybak MJ. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniaein an in vitro infection model. Antimicrob Agents Chemother. 2000;44(3):598-601.
111.
Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials [see Comments]. JAMA. 1998;279(2):125-129.
112.
Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37(5):1073-1081.
113.
Forrest A, Chodosh S, Amantea MA, Collins DA, Schentag JJ. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother. 1997;40(Suppl A):45-57.
114.
Tran JQ, Ballow CH, Forrest A, et al. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. J Antimicrob Chemother. 2000;45:9-17.
115.
Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 1998;42(3):521-527.
116.
Lacy MK, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother. 1999;43(3):672-677.
117.
Lister PD, Sanders CC. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother. 1999;43(1):79-86.
118.
Lister PD, Sanders CC. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniaein an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1999;43(5):1118-1123.
119.
Coyle EA, Rybak MJ. Evaluation of the activity of the newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae (SP) [abstr]. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999.
120.
MacGowan AP, Bowker KE, Wootton M, Holt HA. Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and Streptococci of lancefield groups A and G. J Antimicrob Chemother. 1999;44(6):761-766.
121.
Vostrov SN, Kononenko OV, Lubenko IY, Zinner SH, Firsov AA. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. Antimicrob Agents Chemother. 2000;44(4):879-884.
122.
Firsov AA, Vasilov RG, Vostrov SN, Kononenko OV, Lubenko IY, Zinner SH. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model. J Antimicrob Chemother. 1999;43:483-490.
123.
Pankuch GA, Jacobs MR, Appelbaum PC. Post-antibiotic and post-antibiotic subMIC effect of gatifloxacin against gram-positive and -negative bacteria. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999.
124.
Boswell FJ, Andrews JM, Wise R.Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram- negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect. Antimicrob Agents Chemother. 1997;41(6):1377-1379.
125.
Moore T, Coleman K, Donald B, Rittenhouse S.Postantibiotic effect (PAE) of gemifloxacin (SB-265805) and ciprofloxacin against gram-positive and gram-negative organisms. In: 39th Interscience Conference on Antimicrobial Agents and Chemo-therapy, San Francisco, 1999.
126.
Mackenzie FM, Gould IM. The post-antibiotic effect. J Antimicrob Chemother. 1993;32:519-537.
127.
Credito KL, Davis TA, Kelly LM, Pautuch GA, Jacobs MR, Appelbaum PC. Post-antibiotic effect (PAE) of gemifloxacin (SB 265805) compared with five other quinolones against pneumococci. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999.
128.
Cars O, Odenholt-Tornqvist I.The post-antibiotic sub-MIC effect in vitro and in vivo. J Antimicrob Chemother. 1993;31(Suppl D):159-166.
129.
Zhanel GG, Hoban DJ, Harding GKM. Subinhibitory antimicrobial concentrations: a review of in-vitro and in-vivo data. Can J Infect Dis. 1992;3(4):193-201.
130.
Licata L, Smith CE, Goldschmidt RM, Barrett JF, Frosco M.Comparisons of the post-antibiotic and post-antibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureusand Streptococcus pneumoniae. Antimicrob Agents Chemother. 1997;41:950-955.
131.
Drlica K.A strategy for fighting antibiotic resistance. ASM News. 2001;67:27-33.
132.
Blondeau JM, Xilin A, Hansen G, Drlica K.A mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45(2):433-438.
133.
Smith HJ, Nichol KA, Walkty A, Zhanel GG, Hoban DJ. Molecular characterization and mutant prevention concentration (MPC) determination of single-step fluoroquinolone resistant mutants of S. pneumoniae. In: Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001.
